Date: 2018-01-08

Type of information: Production agreement

Compound: SPEAR T-cell therapies

Company: Adaptimmune (UK) Cell and Gene Therapy Catapult (UK)

Therapeutic area: Technology - Services

Type agreement: production - manufacturing

Action mechanism: cell therapy/gene therapy/immunotherapy product



  • • On January 8, 2018, Adaptimmune Therapeutics announced  an agreement with Cell and Gene Therapy Catapult for vector production in the UK, which will ensure vector supply for its ongoing and future clinical studies. This agreement will enable Adaptimmune to have its own dedicated vector manufacturing space in the UK. It will ensure vector supply production beyond 2020 for ongoing studies with all three SPEAR T-cell therapies, MAGE-A4, MAGE-A10 and AFP. The module, in which Adaptimmune will use its own novel vector manufacturing process and be responsible for operation of the manufacturing process, is located in the UK-based CGT Manufacturing Centre.
  • Adaptimmune has also  successfully manufactured the first SPEAR T-cells for a patient at its Navy Yard facility in Philadelphia. These cells will be used for a patient in the first dose cohort of the ongoing MAGE-A4 multiple tumor study in bladder, melanoma, head & neck, ovarian, non-small cell lung, esophageal, and gastric cancers. The manufacturing facility at the Navy Yard can deliver cells for up to 300 patients per year, with the possibility of expansion that would enable manufacture for up to 1000 patients per year.

Financial terms:

Latest news:

Is general: Yes